Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Metformin Monotherapy.

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Metformin Monotherapy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CANTATA-D
  • Sponsors Janssen Research & Development; Janssen-Cilag; Johnson & Johnson

    • Most Recent Events

    • 08 Jul 2022 Results of post-hoc analysis of five studies (NCT01081834, NCT01106677, NCT00968812, NCT01032629 & NCT01989754) assessing efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method, published in the Diabetologia.
    • 08 Jan 2018 Results (n=2536) of pooled analysis of NCT01106625, NCT01106677, NCT01137812 and NCT02025907 trials assessing effect of Canagliflozin on health related quality of life and patients' satisfaction published in The Patient - Patient-Centered Outcomes Research
    • 15 Sep 2017 Results of a post-hoc analysis assessing the effect of Canagliflozin on liver function tests and liver fibrosis in patients from four phase III trials (CANTATA-M, CANTATA-MSU, CANTATA-D and CANTATA-MP) presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top